MX380780B - TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR. - Google Patents

TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.

Info

Publication number
MX380780B
MX380780B MX2018012456A MX2018012456A MX380780B MX 380780 B MX380780 B MX 380780B MX 2018012456 A MX2018012456 A MX 2018012456A MX 2018012456 A MX2018012456 A MX 2018012456A MX 380780 B MX380780 B MX 380780B
Authority
MX
Mexico
Prior art keywords
cancer
combination therapy
methyl
acceptable salt
pi3k
Prior art date
Application number
MX2018012456A
Other languages
English (en)
Other versions
MX2018012456A (es
Inventor
Bharvin Kumar Patel
Michele C Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2018012456A publication Critical patent/MX2018012456A/es
Publication of MX380780B publication Critical patent/MX380780B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Medicamentos para usarse en el tratamiento y métodos de tratamiento de leucemia linfoblástica aguda de células T, leucemia linfoblástica aguda, leucemia mielógena aguda, leucemia miel+ógena crónica, cáncer de mama, cáncer de ovario, melanoma, cáncer de pulmón cáncer pancreático, glioblastoma, sarcoma, tumores desmoides, carcinoma adenoide quístico, cáncer colorrectal, cáncer de la cabeza y el cuello, cáncer cervical, cáncer de próstata, cáncer de hígado o cáncer de piel en un paciente, que comprenden una terapia de combinación con 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hidroxietil)-6-oxo-7H-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, o una sal o hidrato farmacéuticamente aceptable de la misma, y 8-[5-(1-hidroxi-1-metiletil)piridin-3-il]-1-[(2S)-2-metoxipropil]-3-metil-1,3-dihidro-2H-imidazol[4,5-c]quinolin-2-ona, o una sal farmacéuticamente aceptable de la misma.
MX2018012456A 2016-04-12 2017-04-05 TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR. MX380780B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662321307P 2016-04-12 2016-04-12
PCT/US2017/026099 WO2017180385A1 (en) 2016-04-12 2017-04-05 Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer

Publications (2)

Publication Number Publication Date
MX2018012456A MX2018012456A (es) 2019-03-07
MX380780B true MX380780B (es) 2025-03-12

Family

ID=58548918

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012456A MX380780B (es) 2016-04-12 2017-04-05 TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.

Country Status (11)

Country Link
US (1) US11564929B2 (es)
EP (1) EP3442528B1 (es)
JP (2) JP6911048B2 (es)
KR (1) KR102418766B1 (es)
CN (1) CN109310685B (es)
AU (1) AU2017249988C1 (es)
CA (1) CA3020918A1 (es)
ES (1) ES2898952T3 (es)
MX (1) MX380780B (es)
RU (1) RU2754452C2 (es)
WO (1) WO2017180385A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
MX380780B (es) 2016-04-12 2025-03-12 Lilly Co Eli TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.
AU2017249078B2 (en) 2016-04-12 2022-10-20 Eli Lilly And Company Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
CN110461335A (zh) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
KR102845789B1 (ko) 2017-11-01 2025-08-14 주노 쎄러퓨티크스 인코퍼레이티드 B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
US12193994B2 (en) * 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
AU2022205447A1 (en) * 2021-01-08 2023-07-27 Lantern Pharma Inc. Treatment of brain metastases and cns metastases using illudins or hydroxylureamethyl acylfulvene

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970705A2 (en) 1996-12-23 1998-10-31 Warren J. Porter CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
AU768269B2 (en) 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
WO2007004743A1 (en) 2005-07-05 2007-01-11 Fujifilm Corporation Copolymer and polymerizable composition
JP4822751B2 (ja) 2005-07-05 2011-11-24 富士フイルム株式会社 共重合体およびその製造方法
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
BRPI0815135A2 (pt) 2007-08-14 2015-02-03 Lilly Co Eli Derivados de azepina como inibidores de gama secretase.
KR20100101624A (ko) 2008-01-11 2010-09-17 에프. 호프만-라 로슈 아게 암 치료를 위한 감마-세크레타제 저해제의 용도
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
US20120213029A1 (en) * 2009-08-26 2012-08-23 Frxsh Ag Apparatus and method for mixing of a material to be mixed
WO2011060051A1 (en) 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma
CN102085372A (zh) * 2009-12-04 2011-06-08 中国医学科学院基础医学研究所 Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
JP5737903B2 (ja) 2010-10-26 2015-06-17 三菱重工業株式会社 航空機用配管支持構造
JO3003B1 (ar) * 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
JO3148B1 (ar) 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
JP6720075B2 (ja) 2013-05-31 2020-07-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌のための併用療法
JP6586087B2 (ja) 2013-08-20 2019-10-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
SG10201913841SA (en) 2015-07-24 2020-03-30 Oncotracker Inc Gamma secretase modulators for the treatment of immune system dysfunction
MX380780B (es) 2016-04-12 2025-03-12 Lilly Co Eli TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.
AU2017249078B2 (en) 2016-04-12 2022-10-20 Eli Lilly And Company Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
CN109562114A (zh) 2016-08-31 2019-04-02 伊莱利利公司 用于治疗实体瘤的给药方案
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor

Also Published As

Publication number Publication date
US20210177859A1 (en) 2021-06-17
KR102418766B1 (ko) 2022-07-08
JP7278331B2 (ja) 2023-05-19
RU2018138626A (ru) 2020-05-13
CA3020918A1 (en) 2017-10-19
ES2898952T3 (es) 2022-03-09
JP2019511529A (ja) 2019-04-25
RU2754452C2 (ru) 2021-09-02
EP3442528B1 (en) 2021-05-26
KR20180129917A (ko) 2018-12-05
CN109310685B (zh) 2021-10-29
CN109310685A (zh) 2019-02-05
JP2021169474A (ja) 2021-10-28
MX2018012456A (es) 2019-03-07
JP6911048B2 (ja) 2021-07-28
US11564929B2 (en) 2023-01-31
RU2018138626A3 (es) 2020-09-21
AU2017249988B2 (en) 2022-10-27
EP3442528A1 (en) 2019-02-20
AU2017249988A1 (en) 2018-11-01
AU2017249988C1 (en) 2023-02-16
WO2017180385A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
MX380780B (es) TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.
MX380779B (es) Terapia combinatoria con inhibidores notch y cdk4/6
ZA201807585B (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
Strickland et al. Targeting drivers of melanoma with synthetic small molecules and phytochemicals
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
PH12019500892A1 (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
MX2021002886A (es) Terapia de combinacion para el tratamiento de cancer de mama triple negativo.
RU2017131430A (ru) Способ лечения рака, ассоциированного с мутацией ras
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
PH12013502099A1 (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one for use in the treatment of adenoid cystic carcinoma
TN2018000338A1 (en) Methods of treating pediatric cancers
BR112018002941A2 (pt) métodos para tratar câncer pancreático metastático usando terapias de combinação compreendendo irinotecano lipossomal e oxaliplatina
MX2016008362A (es) Combinaciones farmaceuticas.
MY164705A (en) Imidazo [4,5-c] quinolin - 2 - one compound and its use as pi3 kinase / mtor dual inhibitor
NZ589269A (en) Combination therapy with an antitumor alkaloid
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
PH12018502422A1 (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2010136168A8 (en) Continuous administration of cilengitide in cancer treatments
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
WO2014115859A3 (ja) 分子標的併用腫瘍治療・予防薬
MX2022002179A (es) Combinacion de poziotinib con inhibidores del vegfr2 y sus metodos de utilizacion.
NZ742470A (en) Combination therapy for cancer
HK40051941A (en) Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
Worden et al. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.